title: Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo.
abstract: Intrahepatic cholangiocarcinoma (ICC) has been reported to be the second most common primary hepatic carcinoma worldwide, and very limited therapies are currently available. Serine threonine tyrosine kinase (STYK1), a member of the receptor tyrosine kinase family, exhibits tumorigenicity in many types of cancers and is a potential therapeutic target for ICC. In this study, STYK1 was knocked down in the ICC cell lines HCCC-9810 and RBE via a lentivirus-mediated system using short hairpin RNA (shRNA). Next, cell proliferation, colony formation, cell cycle progression, tumor formation in nude mice, migration and invasion, and the expression levels of cell cycle proteins in Lv-sh STYK1- or Lv-sh Con-infected cells were analyzed by CCK-8 assay, colony formation evaluation, flow cytometry, tumor formation evaluation, wound scratch assay, transwell assay, and western blotting. The results indicated that depletion of STYK1 inhibits ICC development both in vitro and in vivo.
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China.
authors.forename: Mei-Yuan
authors.initials: MY
authors.lastname: Chen
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China. jjx731003@163.com.
authors.forename: Jian-Xin
authors.initials: JX
authors.lastname: Jiang
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China. chengyisun2014@163.com.
authors.forename: Cheng-Yi
authors.initials: CY
authors.lastname: Sun
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Yu
authors.affiliation: Department of Biliary-Hepatic Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang, 550001, China.
authors.forename: She
authors.initials: S
authors.lastname: Tian
mesh_terms: D000818:Animals; D017209:Apoptosis; D001650:Bile Duct Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015153:Blotting, Western; D016022:Case-Control Studies; D002453:Cell Cycle; D002465:Cell Movement; D049109:Cell Proliferation; D018281:Cholangiocarcinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D012333:RNA, Messenger; D034741:RNA, Small Interfering; D020794:Receptor Protein-Tyrosine Kinases; C482299:STYK1 protein, human
keywords: Biomarker; Gene therapy; Intrahepatic cholangiocarcinoma (ICC); Molecular mechanism; STYK1